Relay Therapeutics shareholders elect three directors, approve executive pay and auditor at 2023 annual meeting

Proposal 2. Non-binding advisory vote on executive compensation. The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 97,777,468.59 6,901,684.00 70,089.00 7,473,432.40

Proposal 1. Election of directors. The Company’s stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company’s 2026 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Name Votes For Votes Withheld Broker Non-Votes Douglas S. Ingram 103,319,668.59 1,429,573.00 7,473,432.40 Sekar Kathiresan, M.D. 104,644,413.59 104,828.00 7,473,432.40 Jami Rubin 94,814,052.83 9,935,188.75 7,473,432.40

Proposal 3. Ratification of appointment of independent registered public accounting firm. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstain Broker Non-Votes 112,171,015.00 11,640.00 40,019.00 0.00